Aligos Therapeutics announced that dosing in the Phase 2a HERALD study of ALG-055009 has been initiated in subjects with metabolic dysfunction-associated steatohepatitis MASH .”Dosing the first subjects in our Phase 2a HERALD study is an important milestone for Aligos,” said Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer at Aligos Therapeutics. “We are pleased by the engagement of the clinicians and subjects, demonstrating the need for additional oral MASH therapies. We look forward to continuing to advance this potent, potential best-in-class drug candidate through the clinic.”…Topline safety and efficacy data from this study are expected in Q4.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALGS:
- Aligos presents data at APASL 2024 from ALG-055009, ALG-000184 studies
- Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
- Aligos Therapeutics initiates Phase 2a HERALD study of ALG-055009
- Aligos Therapeutics on the Brink: The Urgent Race to Maintain Nasdaq Listing and Avoid Delisting Consequences
- Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results